Stevenage Bioscience Catalyst (SBC) is an open innovation campus driving collaboration to improve healthcare. Opened in February 2012 to bring together academia, industry, the NHS and other players in the UK life sciences sector, SBC now has 49 tenants which have raised more than £200m during the past 5 years. A five-year celebration event will be held later in 2017, which will showcase campus success stories and discuss plans for Phase 2 of SBC's development.
Stevenage Bioscience Catalyst's stakeholders are GlaxoSmithKline, Wellcome, the Department for Business, Energy and Industrial Strategy (formerly the Department for Business, Innovation and Skills), and Innovate UK. They continue to be supportive as plans for Phase 2 of the campus are developed.
Martino Picardo, CEO of Stevenage Bioscience Catalyst, said, 'SBC's first five years have been a great success, and I would like to thank everyone, including our stakeholders, for their enthusiasm, support and hard work. Over the next five years we will continue to focus on working collaboratively to help grow the life sciences sector in the UK, starting with the East of England Science and Innovation Audit in Life Sciences, which we are leading.'